Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Portola’s Betrixaban Data Pass Muster With FDA?

This article was originally published in The Pink Sheet Daily

Executive Summary

Portola says that it does not expect it will need to do a second Phase III study to get FDA approval for betrixaban, after missing major endpoint in APEX, but analysts have doubts.

Advertisement

Related Content

Portola's Bevyxxa Poised To Capture Niche Novel Anticoagulant Market
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
Keeping Track: Janssen Gets A Breakthrough Therapy Status, FDA Awards Two Orphan Drug Designations, Portola Lands A CRL
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff
Enriched Trials Not Just About Marker-Positive Patients, FDA Says
Clinical Trial Enrichment Could Require Post-Market Studies, Labeling To Address Shortcomings
Back To The Drawing Board For Portola After Merck Returns Betrixaban
Momentum Grows For Novel Oral Anticoagulants Out To Replace Warfarin

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS079252

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel